Evolution, rna-seq: Disease etiology to treatment.

Sofia M. Rodríguez*

Department of Genetics, University of Barcelona, Spain

Introduction

This collection of studies provides critical insights into the complex interplay between evolution and human disease, alongside the burgeoning applications of RNA sequencing in modern medicine. We learn, for instance, how human disease genes can evolve convergently across different species or even within distinct genomic regions. This phenomenon points to shared evolutionary pressures or underlying mechanisms that contribute to susceptibility to similar disorders, offering a deeper understanding of fundamental disease biology and potential avenues for therapeutic intervention [1].

Parallel to this, researchers are actively exploring the adaptive evolution of disease susceptibility genes. It turns out that certain genetic variants, while possibly conferring an advantage in particular historical or environmental contexts, might also increase disease risk in contemporary settings. This highlights the intricate balance between our evolutionary heritage and current health challenges [3].

Further broadening this evolutionary lens, evolutionary genomics has made significant strides over the past decade in deciphering host-pathogen interactions. Genomic approaches vividly illustrate the co-evolutionary arms race, allowing us to pinpoint genes crucial for resistance and susceptibility to infectious diseases, and offering valuable insights into the adaptive landscapes that shape host immunity [6].

Another fascinating evolutionary perspective delves into long non-coding RNAs (lncRNAs). These molecules, though often less conserved than protein-coding genes, demonstrate dynamic evolution leading to species-specific regulatory functions. Understanding their evolutionary origins and conservation is increasingly important, as they contribute to unique disease susceptibilities across different lineages [8].

The application of evolutionary analysis extends further to gene regulatory networks, exploring their conservation and divergence across species. This work is pivotal in clarifying the evolutionary origins of disease susceptibility and identifying critical regulatory nodes whose perturbation can lead to pathological conditions [10].

Beyond evolutionary considerations, RNA sequencing is rapidly transforming clinical diagnostics and precision medicine. This advanced technology is now increasingly adopted in the clinical diagnosis of rare genetic diseases. It offers a powerful means to identify non-coding variants, subtle splicing defects, and gene expression abnormalities that often evade detection by traditional DNA-based sequencing methods, thereby significantly improving diagnostic rates for challenging cases [2].

The utility of RNA sequencing extends widely into precision medicine, where it informs disease diagnosis, prognosis, and the selection of appropriate therapies. Despite facing technical and analytical challenges, the integration of transcriptomic data into routine clinical practice promises to revolutionize personalized healthcare [4].

A specialized, yet incredibly powerful, derivative is single-cell RNA sequencing (scRNA-seq). This technique is having a profound impact by unraveling the cellular heterogeneity and complex gene expression patterns characteristic of human diseases. scRNA-seq empowers researchers to identify specific disease-associated cell types, characterize novel biomarkers, and grasp disease mechanisms with unprecedented resolution, laying groundwork for highly targeted therapies [7].

Moreover, a foundational aspect of RNA biology, splicing, is critically implicated in disease. RNA splicing defects are a significant focus, as dysregulated splicing can lead to aberrant protein products or altered gene expression, contributing to a wide spectrum of genetic disorders and cancers. Consequently, identifying and targeting these mechanisms represent promising therapeutic strategies [5].

Lastly, RNA sequencing finds a vital role in pharmacogenomics, a field dedicated to personalizing drug therapy based on an individual's genetic makeup. Transcriptomic data can effectively predict drug response, pinpoint biomarkers for adverse drug reactions, and optimize treatment regimens by revealing dynamic changes in gene expression relevant to drug metabolism and drug efficacy [9].

***Correspondence to:** Sofia M. Rodríguez, Department of Genetics, University of Barcelona, Spain. E-mail: sofia.rodriguez@genomicsu.es

Received: 07-Jul-2025, Manuscript No. aarrgs-25-274; **Editor assigned:** 09-Jul-2025, Pre QC No. aarrgs-25-274 *(PQ)*; **Reviewed:** 29-Jul-2025, QC No. aarrgs-25-274; **Revised:** 07-Aug-2025, Manuscript No. aarrgs-25-274 *(R)*; **Published:** 18-Aug-2025, DOI: 10.35841/aarrgs-7.4.274

Citation: Rodríguez SM. Evolution, rna-seq: Disease etiology to treatment. J Res Rep Genet. 2025;07(04):274.

Conclusion

This collection of studies thoroughly explores the intricate relationship between human disease and both evolutionary biology and advanced RNA sequencing technologies. A significant theme revolves around the evolutionary origins of disease susceptibility. Research highlights how human disease genes can evolve convergently across different species or genomic regions, suggesting shared evolutionary pressures leading to similar disorders. This understanding can reveal fundamental disease biology and potential therapeutic targets. Similarly, adaptive evolution of disease susceptibility genes shows how certain genetic variants, beneficial in past environments, might increase disease risk in modern contexts, demonstrating the complex interplay between our evolutionary history and contemporary health challenges. Evolutionary genomics also illuminates host-pathogen interactions, mapping the coevolutionary arms race and identifying genes critical for immunity. Moreover, the dynamic evolution of long non-coding RNAs and their role in species-specific disease susceptibilities, alongside evolutionary analyses of gene regulatory networks, further deepen our understanding of disease origins.

Alongside these evolutionary insights, RNA sequencing emerges as a transformative technology in clinical medicine. It is increasingly adopted for diagnosing rare genetic diseases, effectively identifying non-coding variants, splicing defects, and gene expression abnormalities often missed by DNA-based methods, thereby improving diagnostic rates. This powerful tool extends into precision medicine, guiding disease diagnosis, prognosis, and therapeutic selection. Its specialized application, single-cell RNA sequencing, is crucial for dissecting cellular heterogeneity and gene expression patterns in diseases, leading to the identification of novel biomarkers and targeted therapies. Furthermore, RNA sequencing is vital in pharmacogenomics, allowing for personalized drug therapy by predicting drug responses and optimizing treatment regimens based on dynamic gene expression changes. The critical role of RNA splicing defects in various human diseases is also emphasized, with dysregulated splicing contributing to a wide spectrum of disorders and offering new therapeutic targets. Together, these studies paint a comprehensive picture of disease etiology, diagnostics, and treatment approaches, from deep evolutionary roots to cutting-edge molecular interventions.

References

1. Doyoung K, Jinyeong C, *Wankyu K. Convergent evolution of human disease genes. Genome Biol.* 2021;22:181.
2. Viviane K, Nicole WLM K, Eva H B. RNA sequencing in clinical diagnostics of rare diseases: a state-of-the-art review. *Eur J Hum Genet.* 2021;29:1195-1205.
3. Santiago AN, Kevin LM, *Christopher CC. Adaptive evolution of disease susceptibility genes. Hum Genet.* 2021;140:1421-1435.
4. Shanshan Z, Jianming L, Hongxing L. RNA sequencing in precision medicine: Applications, challenges, and future directions. *Brief Funct Genomics.* 2020;19:228-239.
5. Zhaorui D, Pengcheng L, Liang T. RNA splicing and disease: a new perspective. *Signal Transduct Target Ther.* 2020;5:208.
6. Nicholas O, Megan BT, Jean-François GVL. Evolutionary genomics of host-pathogen interactions: *A decade of progress. Evol Appl.* 2020;13:2795-2808.
7. Bokyung H, Jin YS, Hyerim B. Single-cell RNA sequencing: *A powerful tool for dissecting human diseases. BMB Rep.* 2021;54:218-228.
8. Jin L, Qian W, Yunlong L. Evolutionary perspectives on long non-coding *RNAs in disease. J Med Genet.* 2020;57:585-593.
9. Xinyu H, Qianqian L, Ruicheng D. RNA sequencing in pharmacogenomics: current applications and future directions. *Pharmacogenomics.* 2022;23:295-309.
10. Linlin C, Li Z, *Qing Z. Evolutionary analysis of gene regulatory networks in human disease. Comput Struct Biotechnol J.* 2020;18:2470-2479.

Citation: *Rodríguez SM. Evolution, rna-seq: Disease etiology to treatment. J Res Rep Genet. 2025;07(04):274.*